Steven Paul compensation by year
Karuna Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $575,000 | $645,000 | $700,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $8,031,191 | $11,933,397 | $9,905,953 |
| Non-equity incentive | $287,500 | $549,863 | $609,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $8,550 | $8,700 | $9,150 |
| Total | $8,902,241 | $13,136,960 | $11,224,103 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Karuna Therapeutics, Inc. DEF 14A filed April 27, 2023, accession 0000950170-23-014979, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Karuna Therapeutics, Inc. filed document, accession 0000950170-23-014979. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 43,750 | — | $99.72 |
| Option | 91,040 | — | $131.64 |
| Option | 146,900 | — | $111.97 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Karuna Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
30 Form 4 lines since the FY2022 proxy (filed April 27, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-03-18 | Disposition to the issuer derivative | — | 136,094 | $322.96 | 0 |
| 2024-03-18 | Disposition to the issuer derivative | — | 757,045 | $322.73 | 0 |
| 2024-03-18 | Disposition to the issuer | — | 30,304 | $330.00 | 0 |
| 2024-03-18 | Disposition to the issuer | — | 33,882 | $330.00 | 0 |
| 2024-03-18 | Disposition to the issuer | — | 30,304 | $330.00 | 0 |
| 2024-03-18 | Disposition to the issuer | — | 35,877 | $330.00 | 0 |
| 2024-03-18 | Disposition to the issuer | — | 2,046 | $330.00 | 8,550 |
| 2024-03-18 | Disposition to the issuer derivative | — | 616,703 | $314.00 | 0 |
The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Karuna Therapeutics’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Steven Paul · this page | President and Chief Executive Officer | $11,224,103 |
| Andrew Miller | Chief Operating Officer | $5,774,890 |
| Stephen Brannan | Chief Medical Officer | $4,413,379 |
| Troy Ignelzi | Chief Financial Officer | $4,006,465 |
| Charmaine Lykins | Chief Commercial Officer | $759,650 |
Board service
Karuna Therapeutics board · FY2022How this board is paid
Company policy: Karuna Therapeutics pays directors a $45,000 cash retainer. As stated in Karuna Therapeutics's FY2022 proxy.
The full Karuna Therapeutics compensation record
free company briefThis page is one person within Karuna Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Karuna Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Karuna Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.